# EDGAR Filing Document

**Accession Number:** 0001388658
**File Stem:** 0001388658-26-000017
**Filing Date:** 2026-3
**Character Count:** 11279
**Document Hash:** 62640037948931dbf039983ff8de4d9f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001388658-26-000017.hdr.sgml**: 20260312

**ACCESSION NUMBER**: 0001388658-26-000017

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260312

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260312

**DATE AS OF CHANGE**: 20260312

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** iRhythm Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001388658
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 413421287
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37918
- **FILM NUMBER:** 26748451

**BUSINESS ADDRESS:**
- **STREET 1:** 699 8TH STREET
- **STREET 2:** SUITE 600
- **CITY:** San Francisco
- **STATE:** CA
- **ZIP:** 94103
- **BUSINESS PHONE:** 415-632-5700

**MAIL ADDRESS:**
- **STREET 1:** 699 8TH STREET
- **STREET 2:** SUITE 600
- **CITY:** San Francisco
- **STATE:** CA
- **ZIP:** 94103

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** iRhythm Technologies, Inc.
- **DATE OF NAME CHANGE:** 20111021

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IRhythm Technologies, Inc.
- **DATE OF NAME CHANGE:** 20110429

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IRhythm Technologies Inc
- **DATE OF NAME CHANGE:** 20070201

?xml version='1.0' encoding='ASCII'? irtc-20260312

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): March 12, 2026**

**iRhythm Holdings, Inc.** 

**(Exact name of Registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37918** | **41-3421287** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(Commission<br>File Number)** | **(I.R.S. Employer<br>Identification Number)** |

---

**699 8th Street, Suite 600** 

**San Francisco, California 94103** 

**(Address of principal executive office) (Zip Code)**

**(415) 632-5700** 

**(Registrant's telephone number, including area code)**

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common Stock, Par Value $0.001 Per Share | IRTC | The NASDAQ Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Effective as of March 12, 2026, the Board of Directors (the "Board") of iRhythm Holdings, Inc., a Delaware corporation (the "Company") appointed Jason Patten as a director of the Board and member of the Audit Committee of the Board (the "Audit Committee"). Mr. Patten shall hold office for a term expiring at the 2026 Annual Meeting of the Company's stockholders.

There is no arrangement or understanding between Mr. Patten and any other persons pursuant to which Mr. Patten was selected as a director. Mr. Patten is not a party to, nor has any direct or indirect material interest in any transaction with the Company required to be disclosed under Item 404(a) of Regulation S-K. The Board determined that Mr. Patten qualifies as an independent director pursuant to the Securities Act of 1933, as amended, and the listing standards of the Nasdaq Stock Market, in each case as currently in effect and meets the further audit committee standards required by Securities and Exchange Commission ("SEC") Rule 10A-3. Mr. Patten will also enter into the Company's standard form of indemnification agreement for its directors and executive officers, which was filed as Exhibit 10.8 to the Company's Annual Report on Form 10-K (File No. 001-37918) filed with the SEC on February 19, 2026.

Consistent with the Company's compensation policy for non-employee directors (the "Director Compensation Policy"), upon appointment, Mr. Patten was granted an initial retainer grant of restricted stock units with a grant date value of $300,000 vesting annually over the three years following March 12, 2026. Mr. Patten will also receive the customary annual compensation paid to non-employee directors in the form of a cash retainer, paid quarterly in arrears, for his service on the Board and the Audit Committee in an amount consistent with the Director Compensation Policy (currently $55,000 per year for service on the Board and $10,000 per year for service on the Audit Committee). The initial retainer grant will be issued under the Company's 2016 Equity Incentive Plan and will accelerate in full upon a change of control, provided that Mr. Patten remains in service through such change in control.

Prior to being appointed to the Board, Mr. Patten served as an advisor to the Company's President and Chief Executive Officer. In connection with that role, Mr. Patten received a one time payment of $86,771 in cash for services rendered.

**Item 7.01. Regulation FD Disclosure.**

The Company announced the appointment of Mr. Patten to the Board in a press release furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 of this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

------

**Item 9.01 Financial Statements and Exhibits**

**(d) Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press release dated March](jpattenpr_v2.htm)[1](jpattenpr_v2.htm)[2, 2026](jpattenpr_v2.htm)</u> |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **IRHYTHM HOLDINGS, INC.** | **IRHYTHM HOLDINGS, INC.** |
| Date: March 12, 2026 | By: | /s/ Daniel Wilson |
|  |  | Daniel Wilson |
|  |  | Chief Financial Officer |

---

## Exhibit 99.1

![](jpattenpr_v2001.jpg)

iRhythm Holdings Appoints Jason Patten to its Board of Directors SAN FRANCISCO, March 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, is pleased to announce the appointment of Jason Patten to its Board of Directors, effective March 12, 2026. Mr. Patten brings decades of strategic leadership in healthcare, reinforcing iRhythm's commitment to innovation, operational excellence, and long-term growth. "We are thrilled to welcome Jason Patten to our Board of Directors at an important moment in iRhythm's evolution," said Abhi Talwalkar, Chairman of the Board of Directors. "As we scale and expand profitability, we are focused on advancing our platform from episodic detection to proactive, integrated, and increasingly predictive care. Jason's deep experience leading enterprise strategy, innovation, and strategic partnerships at one of the world's largest healthcare organizations will be invaluable as we continue expanding access through primary care, advancing our AI and workflow capabilities, and driving disciplined growth across multiple markets. We look forward to his contributions as we continue building a billion- dollar platform grounded in clinical excellence and long-term value creation." About Jason Patten Mr. Patten currently serves as Executive Vice President and Head of Enterprise Strategy at UnitedHealth Group, a role he has held since January 2022. In this capacity, he leads the company's Corporate Strategy, Strategic Partnerships, and Innovation functions, shaping initiatives that drive organizational impact and sustainable value creation. Prior to his current role, Mr. Patten held key leadership positions at UnitedHealth Group, including Chief Operating Officer and Senior Vice President of OptumHealth, where he focused on optimizing business performance and advancing operational strategy across the company's health services operations. His broad experience underscores a deep understanding of scaling complex enterprises and fostering collaboration across diverse stakeholders. Before joining UnitedHealth Group, Mr. Patten built a strong foundation in financial services and marketing, including global product development at MoneyGram International and strategic marketing roles at Carlson Marketing Group. His interdisciplinary expertise spans growth strategy, partnership development, and organizational transformation. Mr. Patten holds an MBA in Business Administration from University of St. Thomas and a BS in Marketing from Minnesota State University, Mankato. About iRhythm Holdings, Inc. iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all. Investor Contact Stephanie Zhadkevich investors@irhythmtech.com Media Contact Kassandra Perry mediarelations@irhythmtech.com

------